CTLA4 and melorheostosis: The anti–CTLA-4 monoclonal antibody (mAb) ipilimumab improved survival in a phase 3 trial in patients with metastatic melanoma (MEL) 9 and was subsequently approved by the United States Food and Drug Administration for the treatment of patients with advanced MEL.